Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101...
6 insider purchases on record · latest filing 2024-11-27.
Insiders have also filed 19 sale transactions at NGNE.